NGS Streamlines Biomarker Testing in Solid Tumors
Chen, PharmD, MS, BCOP, CPP, discusses the role of next-generation sequencing in improving biomarker testing and treatment planning for solid tumors.
- Experts including Traina, MD, FASCO, and Demetria Smith-Graziani, MD, MPH, share insights on this topic.
- Other contributors include Mark Agulnik, MD, Mrinal M. Guckerman, and Daniel Lefler, MD.
- Additional experts such as Naval G. Daver, MD, Jessica Altman, MD, and Amir T. Firoz, MD, also provide input.
Next-generation sequencing improves biomarker testing and treatment planning in solid tumors.
Authors include Estelamari Rodriguez, MD, MPH, Millie Das, MD, and Ruham Nasany, MD, among others.
Author's Summary
NGS enhances biomarker testing for solid tumors.